Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Añadir filtros

Base de datos
Tópicos
Tipo del documento
Intervalo de año
1.
J Dtsch Dermatol Ges ; 20(10): 1289-1303, 2022 10.
Artículo en Inglés | MEDLINE | ID: covidwho-2074354
2.
J Dtsch Dermatol Ges ; 20(10): 1289-1302, 2022 10.
Artículo en Inglés | MEDLINE | ID: covidwho-2063672

RESUMEN

A fixed drug eruption (FDE) is a common cutaneous adverse drug reaction which occurs following administration of an offending drug. The aim of this review is to provide an update on the list of drugs causing FDE, with a focus on emerging drug culprits reported since the start of the century. Across published literature, triggers for FDE are widely varied. The most frequently implicated drugs include analgesics (nonsteroidal anti-inflammatory drugs [NSAIDs] and paracetamol) and antibiotics. Co-trimoxazole is perhaps the most well described single agent. Since the start of the century there have been over 200 drugs named in case reports on FDE. Newer, novel agents of note include cyclooxygenase-2 specific inhibitors, fluconazole, and phosphodiesterase 5 inhibitors. Other implicated drugs include vaccines, such as various SARS-CoV-2 vaccines. Drugs incriminated in FDE vary based on the geographical region studied and prescribing patterns at a given time. Newer drugs continue to enter the market and are playing an increasing role in the field of FDE. Awareness of rarer culprits and emerging novel agents can help identify a trigger, allowing for prompt withdrawal of the causative agent, preventing recurrence.


Asunto(s)
Vacunas contra la COVID-19 , COVID-19 , Erupciones por Medicamentos , Humanos , Acetaminofén/uso terapéutico , Antibacterianos/uso terapéutico , Antiinflamatorios no Esteroideos/uso terapéutico , Vacunas contra la COVID-19/efectos adversos , Ciclooxigenasa 2/uso terapéutico , Erupciones por Medicamentos/diagnóstico , Erupciones por Medicamentos/tratamiento farmacológico , Erupciones por Medicamentos/etiología , Fluconazol/uso terapéutico , Inhibidores de Fosfodiesterasa 5/uso terapéutico , SARS-CoV-2 , Combinación Trimetoprim y Sulfametoxazol/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA